Ascend Capital’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

Ascend Capital’s Portfolio GEVA Stock Details GEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-85,000	Closed	-$5.85M	–	230
2014 Q3	$5.85M	Buy	+85,000	New	+$6.09M	0.17%	139
2014 Q2	–	Sell	-48,202	Closed	-$4M	–	237
2014 Q1	$4M	Buy	48,202 +22,393	+87%	+$2.07M	0.1%	155
2013 Q4	$1.67M	Buy	25,809 +1,120	+5%	+$66.5K	0.05%	169
2013 Q3	$1.57M	Sell	24,689 -298	-1%	-$14.7K	0.06%	182
2013 Q2	$1.05M	Buy	+24,987	New	+$1.14M	0.04%	160

Other funds holding GEVA

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Ascend Capital's GEVA Position: Q4 2014 in Review

Ascend Capital sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q4 2014, closing a stake of 85,000 shares — an estimated $5.85M sold.

Ascend Capital first reported a position in GEVA in Q2 2013 and held it in 5 quarters. The position peaked at $5.85M in Q3 2014. 126 funds tracked by Wall St. Rank hold GEVA as of Q4 2014.

Ascend Capital reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q4 2014 after selling out during the quarter.
Ascend Capital sold 85,000 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q4 2014, an estimated $5.85M.
Ascend Capital first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q2 2013 and held it in 5 quarters.
Ascend Capital's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $5.85M in Q3 2014.
126 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q4 2014.

Based on Ascend Capital's 13F filing for Q4 2014, filed 13 Feb 2015.